Year-End Report 2008

January - December
• Group revenues from sales of goods and royalties amounted to 1,272 (1,318) MSEK.
• Earnings per share amounted to 0.34 (3.17*) SEK.
• Operating income amounted to 50 (371*) MSEK.
• Revenues within the Esthetics product area amounted to 1,037 (1,073) MSEK and operating income was 172 (533*) MSEK.
• Income after tax amounted to 33 (315*) MSEK.

October - December
• Group revenues from sales of goods and royalties amounted to 336 (336) MSEK during the fourth quarter and operating income amounted to -50 (-10) MSEK.
• Income after tax amounted to -44 (-14) MSEK during the fourth quarter. The results for the fourth quarter include a restructuring cost of 31 MSEK and external costs of 35 MSEK in connection with Ivytan AB’s bid for Q-Med.

Important events after the end of the year
• Q-Med has obtained registration approval for Restylane® in China.
• Q-Med and Palomar Medical Technologies, Inc., have terminated the international distribution agreement that was entered into in January 2008.
• At Q-Med’s Extraordinary General Meeting on February 4 a resolution was adopted to re-elect Bertil Hult, Anders Milton and Bengt Ågerup as Board members of Q-Med. Ulf Mattsson, Tomas Nicolin and Kristina Persson were newly elected. The meeting also elected Anders Milton as Chairman of the Board.
• The Board proposes that no dividend be paid for 2008.

* Operating income for 2007 includes the supplementary purchase sum of 200 MSEK that Q-Med received from Medicis when Restylane Perlane™ was approved for sales in the USA.